Thank you for subscribing!
Next Investors Jul 31, 2024
Our Biotech Investments have been the shining lights in our Portfolio over the last 12 months. Given this form, in June we took a pretty big swing at the INOVIQ (ASX:IIQ) placement and added IIQ to our biotech Portfolio.
Next Investors Jul 11, 2024
There are currently no approved treatments available to help children with Autism Spectrum Disorder (ASD). Our biotech Investment Neurotech International (ASX: NTI) is looking to change this.
Next Investors Jun 12, 2024
Our new Investment Inoviq (ASX: IIQ) is at the forefront of a new frontier in biotechnology.
Next Investors Jun 08, 2024
Biotechs have been a good sector for us over the last 18 months, while the rest of the market was terrible.
Get expert stock analysis direct in your inbox
Next Investors Jun 07, 2024
Our biotech Investment, Arovella Therapeutics (ASX: ALA) is developing an iNKT cell therapy platform to fight cancer, and is setting the stage for a Phase 1 clinical trial. Basically ALA’s treatment can find, identify and kill specific cancer cells, leaving other healthy cells unharmed,
Next Investors Apr 17, 2024
Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.
Next Investors Mar 26, 2024
Our Investment ALA is trialling a technology to find, target and attack ONLY cancer cells, leaving the rest of the body healthy and unimpacted.
Next Investors Mar 20, 2024
We are Invested in Neurotech International (ASX: NTI) - a clinical stage biotech company.
Next Investors Mar 12, 2024
Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB), just announced success on its interim Phase III clinical trial for FSGS - a rare kidney disease.
Join Our Mailing List
